James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.
James Brugarolas, MD, PhD, director of the Kidney Cancer Program, professor of Internal Medicine, and the Sherry Wigley Crow Cancer Research Endowed Chair at the University of Texas Southwestern Medical Center, discusses updated survival data in patients with metastatic renal cell carcinoma (RCC).
According to Brugarolas, the prognosis of patients with metastatic RCC has significantly improved. This improvement has come in to 2 waves, the first with targeted therapies and the second with combination immunotherapy (IO) and tyrosine kinase inhibitors (TKIs). According to Brugarolas, the median survival of patients with metastatic RCC could be approaching 5 years.
0:08 | Well, so the prognosis of patients with metastatic RCC has improved significantly. The first improvement was with targeted therapies. Now the second wave was immunotherapies. And now with the combination of IO/TKI therapies. So, the most recent data we have is that patients nowadays, their median survival could be approaching five years, which is quite significantly improved compared to prior.